<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742105</url>
  </required_header>
  <id_info>
    <org_study_id>CBGT226A1101</org_study_id>
    <nct_id>NCT00742105</nct_id>
  </id_info>
  <brief_title>Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan</brief_title>
  <official_title>A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese
      patients with advanced solid tumor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT) at each dose level</measure>
    <time_frame>22-28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by type, frequency and severity of adverse drug reactions</measure>
    <time_frame>Every 4 weeks</time_frame>
    <description>Safety measures by Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy od BGT226</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Measured by Response Evaluation criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients in which an altered molecular status is detected for markers related to Pl3K signaling</measure>
    <time_frame>Baseline, every 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: Percentage of change, pre- versus post-treatment</measure>
    <time_frame>Every month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>BGT226</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGT226</intervention_name>
    <arm_group_label>BGT226</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  World Health Organization (WHO) Performance Status of ≤ 2

          -  Histologically-confirmed, advanced solid tumors

          -  Progressive, recurrent unresectable disease

          -  Age ≥ 20

        Exclusion Criteria:

          -  Hematopoietic:

          -  No diabetes mellitus or history of gestational diabetes mellitus

          -  No acute or chronic renal disease

          -  No acute or chronic liver disease

          -  No acute or chronic pancreatitis

          -  No impaired cardiac function or clinically significant cardiac diseases such as
             ventricular arrhythmia, congestive heart failure, uncontrolled hypertension

          -  No acute myocardial infarction or unstable angina pectoris within the past 3 months

          -  Not pregnant or nursing and fertile patients must use barrier contraceptives

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3K</keyword>
  <keyword>mTOR</keyword>
  <keyword>Advanced solid tumor</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

